<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057600</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-007</org_study_id>
    <nct_id>NCT03057600</nct_id>
  </id_info>
  <brief_title>Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)</brief_title>
  <official_title>A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in&#xD;
      patients of African ancestry and non-African ancestry with advanced triple negative breast&#xD;
      cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839&#xD;
      will be administered in combination with the full approved dose of paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in&#xD;
      patients of African ancestry and non-African ancestry with advanced triple negative breast&#xD;
      cancer. Multiple single-arm cohorts will be enrolled in which 800 mg BID CB-839 will be&#xD;
      administered in combination with the full approved dose of paclitaxel.&#xD;
&#xD;
      Patients will be enrolled into 4 cohorts, as follows:&#xD;
&#xD;
        -  Cohort 1: patients of African ancestry with 2 or more lines of prior therapy for&#xD;
           metastatic disease&#xD;
&#xD;
        -  Cohort 2: patients of African ancestry with no prior lines of therapy for metastatic&#xD;
           disease&#xD;
&#xD;
        -  Cohort 3: same as cohort 1 but in patients of non-African ancestry&#xD;
&#xD;
        -  Cohort 4: same as cohort 2 but in patients of non-African ancestry&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">November 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be assigned to one of 4 arms depending on the number of prior lines of therapy they have received and whether or not they have African ancestry</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 15 months]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Approximately 18 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Type, incidence, severity, seriousness, and relatedness of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) v.4.0</measure>
    <time_frame>Approximately 15 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - African ancestry, 3rd line+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention = Pac-CB combination&#xD;
Patients must self-identify as African ancestry (AA; includes African American).&#xD;
At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.&#xD;
Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.&#xD;
Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - African ancestry, 1st line</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention = Pac-CB combination&#xD;
Patients must self-identify as African ancestry (includes African American).&#xD;
No prior systemic therapy for advanced or metastatic disease.&#xD;
Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was &gt; 12 mo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Non-AA, 3rd line+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention = Pac-CB combination&#xD;
Patients do not self-identify as African ancestry.&#xD;
Otherwise have the same criteria as Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Non-AA, 1st line</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention = Pac-CB combination&#xD;
Patients do not self-identify as African ancestry.&#xD;
Otherwise have the same criteria as Cohort 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>standard weekly paclitaxel in 28-day cycles</description>
    <arm_group_label>Cohort 1 - African ancestry, 3rd line+</arm_group_label>
    <arm_group_label>Cohort 2 - African ancestry, 1st line</arm_group_label>
    <arm_group_label>Cohort 3 - Non-AA, 3rd line+</arm_group_label>
    <arm_group_label>Cohort 4 - Non-AA, 1st line</arm_group_label>
    <other_name>Taxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839</intervention_name>
    <description>CB-839 administered as oral tablets twice daily (BID)</description>
    <arm_group_label>Cohort 1 - African ancestry, 3rd line+</arm_group_label>
    <arm_group_label>Cohort 2 - African ancestry, 1st line</arm_group_label>
    <arm_group_label>Cohort 3 - Non-AA, 3rd line+</arm_group_label>
    <arm_group_label>Cohort 4 - Non-AA, 1st line</arm_group_label>
    <other_name>telaglenastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Meets criteria for 1 of the 4 defined study cohorts&#xD;
&#xD;
          -  TNBC defined as estrogen receptor (ER) and progesterone receptor (PR) negative (&lt;1%)&#xD;
             and human epidermal growth factor receptor 2 (HER2) negative (fluorescent in situ&#xD;
             hybridization [FISH] negative or immunohistochemistry (IHC) 0-1+)&#xD;
&#xD;
             , progesterone receptor (PR), and .&#xD;
&#xD;
          -  Metastatic disease or locally-advanced disease not amenable to curative intent&#xD;
             treatment&#xD;
&#xD;
          -  Adequate hepatic, renal, cardiac, and hematologic function&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Recovery to baseline or ≤ Grade 1 CTCAE ver.4.0&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Known brain metastases or central nervous system (CNS) cancer unless adequately&#xD;
             treated with radiotherapy and/or surgery and stable for ≥ 2 mo&#xD;
&#xD;
          -  Unable to receive oral medications&#xD;
&#xD;
          -  Known hypersensitivity to Cremophor®-based agents&#xD;
&#xD;
          -  Major surgery within 28 days of C1D1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Whiting, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Brimingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama, Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University - Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer and Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute - Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30332</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JTCC at Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital - UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System (GHS) Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.calithera.com</url>
    <description>Company Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <disposition_first_submitted>December 17, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 29, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 2, 2021</disposition_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>African ancestry</keyword>
  <keyword>African American</keyword>
  <keyword>CB-839</keyword>
  <keyword>Glutaminase Inhibitor</keyword>
  <keyword>Glutaminase</keyword>
  <keyword>TNBC</keyword>
  <keyword>Tumor Metabolism</keyword>
  <keyword>Glutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

